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Abstract
Background:  Current cell-based drug screening technologies utilize randomly integrated
reporter genes to index transcriptional activity of an endogenous gene of interest. In this context,
reporter expression is controlled by known genetic elements that may only partially capture gene
regulation and by unknown features of chromatin specific to the integration site. As an alternative
technology, we applied highly efficient gene-targeting with recombinant adeno-associated virus to
precisely integrate a luciferase reporter gene into exon 1 of the HeLa cell tumor necrosis factor-
alpha (TNF-α) gene. Drugs known to induce TNF-α expression were then used to compare the
authenticity of gene-targeted and randomly integrated transcriptional reporters.
Results:  TNF-α-targeted reporter activity reflected endogenous TNF-α  mRNA expression,
whereas randomly integrated TNF-α  reporter lines gave variable expression in response to
transcriptional and epigenetic regulators. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA),
currently used in cancer clinical trials to induce TNF-α gene transcription, was only effective at
inducing reporter expression from TNF-α gene-targeted cells.
Conclusion: We conclude that gene-targeted reporter cell lines provide predictive indexing of
gene transcription for drug discovery.
Background
Transcriptional regulation provides an ideal target for
therapeutic intervention. As such, tools for studying tran-
scriptional modulators of disease genes will help to facili-
tate the development of novel therapeutics [1]. Cell lines
have been used to study the expression of specific genes
involved in disease development or at signal transduction
checkpoints, and are currently a front-line approach for
early-stage drug discovery. A number of indirect tech-
niques are available to assess gene transcription in cells
including ELISA and gene arrays or quantitative PCR for
measuring the gene transcript levels. However, these
methods are time consuming, resource intensive and/or
do not directly assess the transcriptional activity of an
endogenous promoter. Moreover, they are not amenable
to high-throughput screening (HTS) for efficient detection
of drug-induced changes in disease gene expression.
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Cell-based gene reporter assay systems were developed as
an alternative system amenable to HTS over 10 years ago,
and have been widely used to study transcription and
gene regulation. Specifically, linking easily detectable
reporter genes – such as luciferase, β-galactosidase or
green fluorescent protein – to defined gene promoters and
regulatory elements has resulted in the production of
numerous reporter vectors. Transient transfection of such
reporter vectors into cultured cells and quantitative analy-
sis of the reporter gene product is a fast and efficient way
to study disease gene expression. Moreover, the establish-
ment of cell lines containing random stable integrants has
made possible the development of cell-based reporter
assays [2], which have now been successfully scaled-up for
HTS following advances in robotics and fluorescence/
luminescence plate-reader technologies [3,4]. Recently, a
novel reporter system was developed in which Flp recom-
binase is used to produce flippase recognition target (FRT)
single site-specific integration of a reporter gene construct
at a transcriptionally-active genomic locus in cultured
cells [5]. This approach has several advantages over ran-
domly integrated reporter constructs including single
copy construct integration and a single chromatin context
within which the effects of promoter mutations or single
nucleotide polymorphisms (SNPs) on gene expression
can be studied [5]. Moreover, this reporter system has
been used to screen small molecules for inhibition of the
pro-inflammatory cytokine, tumor necrosis factor (TNF)
[6]. Although randomly integrated and FRT single site-
specific reporters are presumed to reflect endogenous reg-
ulation of the disease gene, this is a questionable assump-
tion given the unknown epigenetic influences of
chromatin structure on gene transcription along with
missing genetic elements that regulate gene expression at
the endogenous locus. To this end, optimal systems
would utilize gene-targeted reporters controlled by endog-
enous regulatory sequences and governed by an inherited
epigenetic program unique to a given disease gene locus.
Although gene targeting in mouse embryonic stem cells
makes it possible to precisely integrate exogenous DNA
sequence into a predetermined 'target' gene locus [7], such
systems have been much less effective in somatic cells. An
alternative approach, utilizing single-stranded recom-
binant adeno-associated virus (rAAV) to promote homol-
ogous recombination between the targeting construct and
the chromosome [8-11] has been widely applied to genet-
ically modify endogenous genes by insertion, deletion/
replacement, and point mutation [11-14]. The efficiency
of gene targeting using single-stranded rAAV vectors is
also much higher than that observed with adenovirus- or
retrovirus-based vector systems [13]. Self-complementary
rAAV (scAAV) vectors have been shown to promote more
efficient viral transduction than single-stranded rAAV vec-
tors both in vitro and in vivo [15]. However, these double-
stranded vectors do not appear to contribute to the gene
targeting reaction [13,16].
The TNF-α gene maps to chromosome 6p21.3, contains
four exons, and spans approximately 3 kb of DNA in
human cells [17,18]. TNF-α gene expression is cell type-
specific and induced by a wide variety of stimuli such as
phorbol 12-myristate 13-acetate (PMA) and lipopolysac-
charide [19-21]. The TNF-α protein is a multifunctional
cytokine, and is involved in the regulation of a broad spec-
trum of biological processes [22-24]. The TNF-α  gene
appears to be silenced in HeLa cells, as evidenced by unde-
tectable levels of mRNA by northern blot and protein by
ELISA [25]. In the present study, we sought to engineer a
HeLa cell line containing a targeted luciferase reporter in
exon 1 of the TNF-α gene. We also sought to compare the
patterns of Renilla  luciferase (R-Luc) induction with
endogenous TNF-α mRNA transcription between targeted
and non-targeted cell lines in response to drug treatment.
The production of a TNF-α gene-targeted reporter cell line
will provide a sensitive and more predictive analytical tool
for identifying molecules that modulate TNF-α gene tran-
scription.
Results and discussion
An rAAV targeting vector (AV.TNF-RL.targ) was generated
to facilitate fusion of the Renilla luciferase (R-Luc) reporter
gene to the TNF-α gene locus in HeLa cells (Figure 1a).
The vector harbors a 2.1 kb genomic DNA fragment from
the  TNF-α  locus, which was split into left and right
homologous arms by the insertion of a R-Luc cDNA and
loxP sites that flank a phosphoglycerate kinase (PGK) pro-
moter-driven Zeocin expression cassette. The insertion
site in exon 1 is immediately downstream of the TNF-α
start codon, fusing the R-Luc gene in-frame to the TNF-α
transcript. Since the left homologous arm of the targeting
vector encodes the TNF-α  core promoter and contains
other regulatory elements necessary for initiation of tran-
scription, we are able to compare reporter expression pro-
files between the targeted and non-targeted cell lines, the
latter of which are derived from the random integration of
AV.TNF-RL.targ in HeLa cells. A Zeocin-resistant gene
serves as a selectable marker for clonal expansion of cells
in which the rAAV genome has been stably integrated.
Enrichment of stably integrated cells is required for this
type of insertional gene targeting.
HeLa cells were infected with AV.TNF-RL.targ (Figure 1a)
and re-plated for clonal expansion under Zeocin selection.
Zeocin-resistant colonies were picked and transferred to
replicate 96-well plates. Cells in replica plates were lysed
for PCR screening with two sets of primers, which hybrid-
ize to sequences outside the right and left targeting arms
and inside the exogenous insert. Clone #28 was identified
as a positive targeted clone, from 192 clones screened, andBMC Biology 2009, 7:8 http://www.biomedcentral.com/1741-7007/7/8
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its left-side PCR product was cloned into the pBlunt4PCR
vector (Invitrogen) for sequence confirmation. Sequenc-
ing results revealed the presence of both the non-virus-
derived flanking sequences and the expected in-frame
fusion of the R-Luc cDNA in the TNF-α gene (data not
shown). This positive clone (designated as Tg#28zeoR)
was expanded and the genomic DNA was analyzed by
digestion with several restriction enzymes (Figure 1b;
lanes 2, 4 and 6). Genomic DNA from parental HeLa cells
was used for comparison (Figure 1b; lanes 1, 3 and 5). The
Southern blot was probed with TNF-α left arm-homolo-
gous sequences. The additional bands observed in the
Adeno-associated virus-mediated TNF-α gene targeting in HeLa cells Figure 1
Adeno-associated virus-mediated TNF-α gene targeting in HeLa cells. (a) Genomic fragment containing the human 
TNF-α gene (top) and the recombinant adeno-associated virus (rAAV) TNF-α targeting vector (bottom). Arrows mark nested 
primers used for PCR screening of targeting events. Restriction sites and probes used for Southern blot confirmation of target-
ing events are also shown. The left and right homologous arms (Homologous Arm) in the AAV targeting vector contain endog-
enous sequence from the wild-type TNF-α allele. (b) Southern blot analysis of cells derived from the targeted intermediate 
clone Tg#28zeoR, using restriction sites and the TNF-α probe indicated in panel (a). Parental HeLa cell genomic DNA is shown 
in lanes 1, 3 and 5 and targeted clone Tg#28zeoR genomic DNA in lanes 2, 4 and 6. (c) Strategy used to generate the final TNF-
α targeted R-Luc reporter cell line by LoxP/Cre-mediated excision of the Zeocin selection cassette. (d) Southern blot analysis 
of the zeocin-resistant targeted intermediate clone (Tg#28zeoR, marked as Z+), and the Zeocin-sensitive targeted cell line 
(Tg#28zeo-, marked as Z-). Arrows to the left of the blots indicate the DNA fragments cut from non-targeted (solid) and gene-
targeted (open) TNF-α alleles. (e) Renilla luciferase (R-Luc) reporter activity in the TNF-α targeted intermediate clone 
Tg#28zeoR, the Tg-Zeo- cell pool following excision of the selection marker, and from 5 individual Tg-Zeo- clonal cell lines (#1–
5) isolated from the Tg-Zeo- cell pool. Results represent the mean (+/-SEM, N = 4). One-way ANOVA demonstrated no signif-
icant difference (p > 0.05) between the targeted cell pool and the five individual targeted clonal cell lines isolated from the pool.BMC Biology 2009, 7:8 http://www.biomedcentral.com/1741-7007/7/8
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digested Tg#28zeoR samples (Figure 1b; lanes 2, 4 and 6)
are indicative of targeted insertion of the R-Luc cDNA at
the TNF-α gene locus. No additional random vector inte-
gration was observed (Figure 1b).
The exogenous PGK promoter and transcription of the
Zeocin gene could affect the transcriptional activity of the
targeted TNF-α gene. To eliminate any possible artificial
induction in R-Luc activity, the selection cassette was
removed from the targeted intermediate, Tg#28zeoR (Fig-
ure 1c). Flanked by a pair of LoxP sites, the PGK-Zeocin
cassette can be easily excised from the targeting AAV
genome. Cre recombinase-mediated excision was used to
remove this selection cassette from the targeted
Tg#28zeoR line and also from the non-targeted cell lines
that harbor random integrations of the targeting virus. A
recombinant adenoviral vector, Ad.Cre, was used to
deliver Cre recombinase to the cells. Southern blot analy-
sis with probes for TNF-α  and PGK/Zeo demonstrated
that Ad.Cre infection resulted in loss of the selection cas-
sette from the targeted intermediate, producing the final
TNF-α reporter cell line, Tg#28zeo- (Figure 1c and 1d).
Individual clones expanded from a single cell were iso-
lated from the Zeocin-sensitive cell pool by limited dilu-
tion. Five independent lines were randomly selected and
basal levels of R-Luc expression among these was com-
pared. No apparent differences were observed between
individual Tg#28zeo- lines, and the expression levels were
very similar to that in the original cell pool (Figure 1e).
However, basal R-Luc activity in the targeted intermediate
was more than 300-fold higher than in the clones lacking
the Zeocin selection cassette (Figure 1e). Thus, as pre-
dicted, this selection marker enhanced transcription from
the  TNF-α  gene locus, arguing that R-Luc activity in
Tg#28zeo- cells should more closely reflect endogenous
TNF-α gene regulation than reporter activity in Tg#28zeoR
cells.
Current TNF-α reporter vectors contain only about 1.0 kb
of core promoter located upstream of the TNF-α  gene
(Invitrogen Corp., Carlsbad, CA; Panomics, Inc., Fremont,
CA). In addition, these plasmid-based TNF-α/reporter
constructs are randomly inserted into the host cell
genome following transfection. In theory, the fidelity of
TNF-α  gene expression in these randomly integrated
reporter cell lines may be influenced by missing regula-
tory sequences (enhancer and/or silencer) not part of the
1.0 kb core promoter of the TNF-α  gene [20,26,27].
Indeed, recent studies have demonstrated that the regula-
tion of TNF-α  expression involves distal enhancers
located over a 12 kb region, and that these enhancers
interact to form a novel double-loop chromatin configu-
ration. This structure circularizes the TNF-α  gene and
thereby facilitates transcription [28-30]. Moreover, epige-
netic regulation is important for the control of TNF-α
transcription [31] and key epigenetic modifications at the
TNF-α locus may be missing from the regulatory elements
governing reporter expression in the randomly integrated
reporter cell lines. In addition to the lack of intact endog-
enous regulatory elements and epigenetic modifications
associated with the self-contained TNF-α core promoter/
reporter gene, expression of the randomly integrated
reporters is very likely to be influenced by both genetic
and epigenetic features associated with the insertion site,
in a very unpredictable manner. Thus, we hypothesized
that the TNF-α gene would be an ideal platform to test
whether targeted reporter expression more closely reflects
endogenous gene expression patterns than randomly inte-
grated reporters.
To test this hypothesis, we isolated 18 non-targeted TNF-
α/R-Luc reporter clones in which the PGK-Zeocin cassette
had been excised by Ad.Cre infection. We then compared
basal R-Luc activity in the targeted and non-targeted
reporter lines. Activity varied widely among the non-tar-
geted lines relative to that in the targeted line. Four non-
targeted (nTg) lines representing the range of basal R-Luc
activity were selected for additional comparison to the
Tg#28zeo- targeted clone (Tg) (Figure 2a). TNF-α mRNA
was purified from the reporter lines and quantified by
TaqMan PCR (Figure 2a). Basal TNF-α mRNA levels were
similar in all of the nTg lines, whereas the level in the Tg
line was somewhat lower. Reduced expression in the Tg
line was most likely due to the disruption of one TNF-α
allele as a consequence of the in-frame insertion of the R-
Luc cDNA. Tg and nTg cell lines were then treated with
known inducers of TNF-α expression. Drugs representing
different activation pathways were used: the protein
kinase C activator phorbol 12-myristate 13-acetate (PMA)
[32,33]; the DNA topoisomerase II inhibitor doxorubicin
(DOX) [34,35]; the histone deacetylase inhibitor trichos-
tatin A (TSA) [31,36]; and the DNA methylation inhibitor
5-aza-2'-deoxycitidine (Aza-dC) [31]. The extent of drug-
induced reporter activity varied dramatically among the
nTg cell lines tested – ranging from little (nTg2) or no
induction (nTg1 and nTg3) to an induction profile similar
to that in the Tg cell line (nTg4) (Figure 2b). However,
even where such similarities existed, differences between
the Tg and nTg4 lines were apparent. Drug-induced
changes in TNF-α and R-Luc mRNA expression in the Tg
line were then quantitated by TaqMan PCR and compared
with R-Luc activity in the Tg line (Figure 2c). The induced
patterns of both the TNF-α  and R-Luc mRNAs closely
reflected the patterns of R-Luc protein activity following
drug treatment, indicating that reporter expression accu-
rately reflects endogenous TNF-α gene expression in the
Tg clone.BMC Biology 2009, 7:8 http://www.biomedcentral.com/1741-7007/7/8
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Throughout the approximately one-year study period, the
basal level of R-Luc activity remained low and the levels of
PMA- and TSA-induced reporter expression remained con-
stant in the targeted cell line (data not shown). However,
we did not conduct a systematic analysis of drug-induced
reporter activity at regular intervals during this time. Nev-
ertheless, while the long-term affects from integration of
reporter gene sequences are unknown, our data do not
indicate a progressive transcriptional silencing of the R-
Luc gene.
We next probed potential regulatory differences between
Tg and the nTg cell lines further by investigating their
responsiveness to 5,6-Dimethylxanthenone-4-acetic acid
(DMXAA) [37]. This is an agent that induces vascular per-
meability and tumor cell death in human solid tumors by
activating TNF-α transcription [38,39] and is currently in
Phase II clinical trials [40]. At a fixed drug concentration,
DMXAA-induced R-Luc activity was observed in the Tg cell
line but not in any of the tested nTg cell lines (Figure 3a).
In DMXAA dose-response studies, R-Luc activity was
induced in the Tg line by as much as ~10-fold, while
induction in the nTg4 line (which was the nTg line that
most closely mirrored Tg line responses by other drugs,
Figure 2b) was insignificant (Figure 3b). This differential
drug-based induction was not due to cell line-dependent
differences in cellular toxicity (Figure 3c). Moreover, little
to no difference was observed when comparing the up-
regulation of TNF-α mRNA following DMXAA treatment
in the Tg and nTg4 lines (Figure 3d). These data suggest
Renilla luciferase activity and TNF-α mRNA expression in TNF-α targeted and non-targeted reporter cell lines Figure 2
Renilla luciferase activity and TNF-α mRNA expression in TNF-α targeted and non-targeted reporter cell lines. 
(a) Basal R-Luc reporter activity and TNF-α mRNA levels in the TNF-α targeted (Tg) cell line and in four non-targeted (nTg #1–
4) cell lines. (b) Relative R-Luc activity in the targeted cell line (Tg) and in four non-targeted cell lines following treatment with 
the TNF-α transcriptional activator PMA (5 ng/ml), DOX (5 μM), TSA (100 ng/ml) or Aza-dC (5 mg/ml). (c) The drug-induction 
profiles of R-Luc activity (top), TNF-α mRNA expression (middle), and R-Luc mRNA expression (bottom) in the Tg cell line. 
Values represent the mean (+/-SEM, N = 4).BMC Biology 2009, 7:8 http://www.biomedcentral.com/1741-7007/7/8
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that the 1.0 kb TNF-α  core promoter region does not
encode the DMXAA response element(s).
Anthracycline antibiotics are also known activators of
TNF-α  promoter transcription. Dose-response studies
with four closely related anthracycline antibiotics demon-
strated a pronounced up-regulation of R-Luc activity in
the Tg cell line at a drug concentration of 1 μM (Figure
4a). Anthracycline exposure did not appear to signifi-
cantly reduce cell viability in the Tg line at this drug con-
centration (Figure 4b). Therefore, both Tg and nTg4 cell
lines were treated with anthracyclines at 1 μM drug and
assayed for R-Luc activity. Differential R-Luc activity was
evident between these cell lines, most notably following
Idarubicin treatment (Figure 4c). Indeed, Idarubicin
induced R-Luc activity ~300-fold in the Tg line, but only
~50-fold in the nTg4 line – representing a 6-fold differ-
ence in induction between the Tg and the nTg4 cell lines.
DMXAA treatment of TNF-α targeted and non-targeted R-Luc reporter cell lines Figure 3
DMXAA treatment of TNF-α targeted and non-targeted R-Luc reporter cell lines. (a) Relative R-Luc activity in the 
targeted (Tg) and non-targeted (nTg #1–4) reporter cell lines in the absence or presence of DMXAA (100 μg/ml). (b) Dose-
response profile for R-Luc activity following treatment of the Tg and nTg4 cell lines with DMXAA. (c) Dose-response profile 
for DMXAA-induced cytotoxicity in Tg and nTg4 cell lines. (d) Induction of TNF-α mRNA in the Tg and nTg4 cell lines follow-
ing treatment with DMXAA. Despite the fact that DMXAA only induces R-Luc reporter activity in the Tg cell line, DMXAA 
induced TNF-α mRNA to equivalent levels in both cell lines. Values represent the mean (+/-SEM, N = 4).BMC Biology 2009, 7:8 http://www.biomedcentral.com/1741-7007/7/8
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Differential induction between Tg and nTg4 cell lines was
also observed following treatment with daunorubicin,
doxorubicin and epirubicin. Again, these differences were
not due to differences in anthracycline-induced cell death
in the Tg and nTg4 cell lines (Figure 4d). Rather, we
attribute the differences in R-Luc reporter activity to
unique genetic and/or epigenetic features of the endog-
enous TNF-α gene locus. We also conclude that targeted
reporter cell lines may be superior tools for screening
drugs that modulate the transcriptional activity of target
genes. The use of such cell lines with biophotonic imaging
as presented here (Figure 4a and 4b) may be extremely
useful for multi-parameter HTS to identify novel thera-
peutics.
Conclusion
We conclude that gene-targeted reporter cell lines may
more accurately index endogenous gene expression to
facilitate predictive cell-based screening for drug discov-
ery.
Methods
Cell culture, virus production and chemical
The human cervical adenocarcinoma cell line HeLa
(ATCC CCL-2) was purchased from American Type Cul-
Anthracycline treatment of TNF-α targeted and non-targeted R-Luc reporter cell lines Figure 4
Anthracycline treatment of TNF-α targeted and non-targeted R-Luc reporter cell lines. (a) Dose-response profile 
of R-Luc activity in the targeted (Tg) cell line treated with four closely related anthracycline antibiotics. Cells treated with Epi-
rubicin were grown on a separate plate. Luciferase activity was assessed using biophotonic imaging on the IVIS. (b) Dose-
response profile of cell viability in the Tg line following anthracycline treatment. The same culture plates that are shown in 'a' 
are also shown in 'b'. Fluorescence was assessed using biophotonic imaging on the IVIS. (c) Relative R-Luc activity in targeted 
(Tg) and non-targeted (nTg4) cell lines following treatment with a fixed concentration of the different anthracyclines (1 μM). 
(d) Anthracycline-induced cytotoxicity in the Tg and nTg4 cell lines was similar. Values represent the mean (+/-SEM, N = 4).BMC Biology 2009, 7:8 http://www.biomedcentral.com/1741-7007/7/8
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ture Collection (ATCC), and the cells were cultured in
DMEM supplemented with 10% FBS. The Cre recombi-
nase-expressing adenovirus vector, Ad.Cre, was obtained
from the Vector Core of the Gene Therapy Center at The
University of Iowa. PMA, DOX, Daunorubicin, Idaru-
bicin, epirubicin, TSA and Aza-dC were purchased from
Calbiochem. DMXAA was purchased from Sigma.
Isolation of TNF-α genomic DNA and generation of the 
TNF-α targeting AAV proviral vector
A 2.8 kb TNF-α DNA fragment was amplified by PCR,
using AccuPrime Pfx supermix (Invitrogen), from
genomic DNA extracted from cultured HeLa cells. Cloning
primers were designed based on the published human
TNF-α sequence (Gene Bank ID: AB202113). The forward
primer used was 5'-GAGCTGTGGGGAGAACAAAAGGA-
3' and the reverse primer used was 5'-TTGGCCCTTGAA-
GAGGACCTG-3'. The TNF-α start codon is located in the
center of the PCR product, and 1.32 kb of the promoter
and 5'untranslated sequences were included. The PCR
product was cloned into the pBlunt4PCR vector using a
Topo cloning kit (Invitrogen) and its identity confirmed
by DNA sequencing. The resultant plasmid was desig-
nated pTopo-TNF2.8. We constructed a PGK promoter-
driven Zeocin expression cassette by replacing the neomy-
cin-resistant gene in pPGKneo with the zeocin resistant
gene, retrieved from pSV40/Zeo (Invitrogen). The result-
ant pPGKzeo plasmid was also flanked by a pair of LoxP
sites. 1.2 kb Renilla luciferase cDNA, plus an SV40 polya-
denylation signal, was retrieved from pRL-SV40
(Promega) and linked to the 5'end of the PGK promoter
in the plasmid pPGKzeo to obtain the cloning intermedi-
ate pRL-PGKzeo. 1.0 kb of the left homologous arm con-
taining the TNF-α promoter and the first translation start
codon was amplified from the plasmid clone pTopo-
TNF2.8 using the forward primer subLF (5'-cccaagcttA-
GAGCCTCCAGGACCTCCAGGTAT-3'; lower-case font
indicates the flanking restriction enzyme sites for cloning)
and the reverse primer subLR (5'-aactttcgaagtCATGGT-
GTCCTTTCCAGGG-3'; bold font indicates the start
codon). The PCR product was cut with HindIII and BstB1
and inserted into the plasmid pRL-PGKzeo, which
resulted in the R-Luc cDNA being fused in frame to the
TNF-α gene at the 3' end of the left homologous arm. The
1.0 kb right homologous arm was also amplified from the
plasmid pTopo-TNF2.8, using the forward primer subRF
(5'-cgagctaGCACTGAAAGCATGATCCGGG-3') and the
reverse primer subRR (5'-ccatcgatGGGTTCGAGAAGAT-
GATCCTGAAG-3'). The PCR product of the right arm, the
DNA fragment containing the R-Luc-fused left arm and
the PGK-Zeocin selectable marker were assembled and
finally cloned into an AAV2 proviral plasmid, giving rise
to a vector that harbors 2.0 kb of TNF-α genomic DNA
fused in frame to the R-Luc cDNA and with a zeocin cas-
sette inserted at the center. The AAV proviral vector was
constructed in our laboratory with the AAV-2 inverted ter-
minal repeats (ITRs) kindly provided by Targeted Genetics
(Seattle, WA). The rAAV-2-targeting virus (AV.TNF-
RL.targ, see Figure 1a) was produced as previously
described, using a triple plasmid transfection procedure in
293 cells, and purified over an iodixanol cushion fol-
lowed by ion exchange HPLC [41]. The genome size of
this single-stranded rAAV targeting vector, including the
ITRs, is 4.7 kb.
Gene targeting and screening of homologous recombinants
5 × 105 HeLa cells were cultured in 60 mm dishes and
infected with AV.TNF-RL.targ at a multiplicity of infection
(MOI) of 100,000 particles per cell. On day 1 post-infec-
tion, HeLa cells were re-plated onto ten 100 mm dishes
and selected in medium containing 150 μg/ml Zeocin for
16 days to allow for the expansion of Zeocin-resistant
clones. One hundred and ninety-two well-separated colo-
nies were picked, and expanded clonally in two 96-well
plates. PCR screening was performed on one confluent
replica plate using primer sequences outside the left vector
homology arm and anchored within the R-Luc cDNA.
Cells in the 96-well plates were then lysed by the addition
of 10 μl per well of lysis buffer (50 mM KCL, 1.5 mM
MgCl2, 10 mM Tris, pH 8.5, 0.5% NP40, 0.5% Tween 20),
and 1/10 of the resultant cell lysate (1 μl) was used for
PCR. The first round PCR primer set was as follows: F1 (5'-
GGAAGCAAAGGAGAAGCTGAGAAGA-3') and intR1 (5'-
AAGCGAAGGAGCAAAGCTGCTA-3'). One-fiftieth of
each first-round PCR product was then used as a template
for the second round of PCR with the following primers:
F2 (5'-GCTCTGAGGAATGGGTTACAGGAG-3') and intR2
(5'-CCCAATCATGGCCGACAAAA-3'). The positive clones
were confirmed by another nested PCR reaction targeting
the right arm of the integration site, using the first round
primer set: intF1 (5'-ACGTGACCCTGTTCATCAGCG-3')
and R1 (5'-CGAGTCCTTCTCACATTGTCTCCAA-3'); and
the second round nested primer set: intF2 (5'-TCGGAG-
GTCGTGTCCACGAACTT-3') and R2 (5'-CCTAGCCCTC-
CAAGTTCCAAGACA-3'). A single clone that was PCR-
positive for both the left and right arms of the predicted
integration event was expanded to 24-well plates, and
eventually to 100 mm dishes, to generate sufficient cells
for the preparation of genomic DNA and Southern blot
confirmation of the integration event. Genomic DNAs
were digested with either AseI or BamHI (both of which
are unique sites in the targeting vector) and AvrII (which
does not cut within the targeting vector). Southern blot-
ting was carried out with a P32-labeled TNF-α left arm
probe or PGK/Zeo probe (see Figure 1). LoxP/Cre-medi-
ated cassette excision was used to remove the PGK/Zeo
cassette from the Zeocin-resistant targeted intermediate
and the AAV integrated non-targeted cells. Zeocin-resist-
ant cells were infected with adenovirus encoding Cre
(Ad.Cre) at 500 MOI per cell. Half of the cells were cul-BMC Biology 2009, 7:8 http://www.biomedcentral.com/1741-7007/7/8
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tured and expanded in normal culture medium, and the
remaining cells were cultured in Zeocin-containing
medium to confirm the loss of drug resistance associated
with Cre-mediated excision. Clonal cell lines were derived
from cells grown in absence of Zeocin by limiting dilu-
tion. Southern blot analysis with TNF-α  and PGK/Zeo
probes was carried out to confirm cassette removal.
Renilla luciferase activity assay and drug-induction
Enzyme activity was determined using the Renilla Luci-
ferase Assay System (Promega) in a 20/20 luminometer
equipped with an automatic injector (Turner Biosystems).
Parental, targeted, and non-targeted HeLa cells were
treated with different chemicals for specific periods of
time prior to assaying luciferase activity. The drug induc-
tion period for PMA, TSA, DMXAA, and the anthracycline
antibiotics (daunorubicin, doxorubicin, idarubicin and
epirubicin) was 24 hours, and the period for Aza-dC was
three days. Cells were dispensed onto 6-well or 24-well
plates one day before drug addition. Cells (2 × 105) were
lysed in 100 μl Renilla luciferase lysis buffer, and 1/10 of
this cell lysate was assayed for luciferase activity. Four par-
allel samples were tested for each drug treatment. Cellular
toxicity was assessed using the CellTiter-Blue Cell Viability
Assay kit from Promega on the IVIS Biophotonic Imaging
system, according to the manufacturer's instructions. In
separate dose response experiments, Renilla  Luciferase
activity was also assessed using the IVIS Biophotonic
Imaging system.
RNA isolation and TaqMan-based PCR quantification
Total RNA was isolated from 1 × 106 cells, with or without
drug treatment, and prepared using the RNAprotect Cell
Reagent and the RNeasy Plus Mini kit (QiaGen). Total
RNA samples eluted in a volume of 30 μl were used
directly for reverse transcription (RT) or purified using the
Micro-FastTract 2.0 mRNA Mini kit (Invitrogen) to enrich
for polyA mRNA. The mRNA samples were resuspended
in 10 μl RNase-free water. RT was performed using the
High Capacity cDNA Reverse Transcription kit (ABI),
through random priming. Either one-sixth (5 μl) of each
total RNA sample or the entire volume of each mRNA
sample (10 μl) was used for RT in a final reaction volume
of 100 μl. The cDNA product (10 μl) from the RT reaction
was used for TaqMan PCR quantification in a final reac-
tion volume of 50 μl, using the TaqMan Universal PCR
Master Mix (Applied Biosystems). A 20× mix of primers
and FAM-labeled probe for the human TNF-α  gene
expression assay were purchased through ABI's Gene
Expression Assay-on-Demand (Assay ID:
Hs00174128_m1). The 20× mix of primers and FAM-
labeled probe for the R-Luc expression assay were custom-
ordered from ABI (Forward: 5'-GTGAAGTTCGTCGTC-
CAACATT-3'; Reverse: 5'-AACGTC AGGTTTACCACCTTT-
TACT-3'; TaqMan probe: 5'-FAM –
CCTCGTGAAATCCCG). The housekeeping gene GAPDH
was used for sample normalization, and the primer-lim-
ited VIC-labeled internal control for the GAPDH assay
was also purchased from ABI. Relative quantification was
performed using the TaqMan assay, and these data were
collected and analyzed using a ABI-Prism 7900 HT Real-
Time PCR Sequence Detection Systems (SDS v2.3). Con-
ditions for the PCR reactions were 2 min at 50°C, 10 min
at 95°C, and 40 cycles each consisting of 15 sec at 95°C
and 1 min at 60°C. The experiments were performed in
triplicate wells in a singleplex format when data were
compared by the relative standard curve method, or in a
multiplex format for both the FAM and VIC signals when
data were analyzed by the comparative CT method.
Authors' contributions
ZY contributed to the design of the study, the collection,
analysis and interpretation of data and preparation of the
manuscript. DL participated in the collection and analysis
of data. JFE and GHL contributed to the conception and
design of the study, analysis and interpretation of data
and manuscript preparation. All authors read and
approved the final manuscript.
Acknowledgements
This work was supported by a grant from the IOWA Centers for Enter-
prise (GHL and JFE), a Battelle Research and Commercialization Award – 
State of Iowa (GHL and JFE) and NIH RO1-DK51315 (JFE). The authors 
wish to thank Chengjie Huang for technical assistance and members of the 
University of Iowa Research Foundation for continued support. We also 
gratefully acknowledge the editorial assistance of Christine Blaumueller 
(University of Iowa).
References
1. Carey M, Smale ST: Transcriptional regulation in eukaryotes: concept,
strategies, and techniques Cold Spring Harbor, NY: CHS Laboratory
Press; 2000. 
2. Kain SR, Ganguly S: Overview of genetic reporter systems.  Curr
Protoc Mol Biol 2001, Chapter 9:Unit 9.6.
3. Swevers L, Kravariti L, Ciolfi S, Xenou-Kokoletsi M, Ragoussis N,
Smagghe G, Nakagawa Y, Mazomenos B, Iatrou K: A cell-based
high-throughput screening system for detecting ecdysteroid
agonists and antagonists in plant extracts and libraries of
synthetic compounds.  Faseb J 2004, 18:134-136.
4. Tang Y, Luo J, Fleming CR, Kong Y, Olini GC Jr, Wildey MJ, Cavender
DE, Demarest KT: Development of a sensitive and HTS-com-
patible reporter gene assay for functional analysis of human
adenosine A2a receptors in CHO-K1 cells.  Assay Drug Dev Tech-
nol 2004, 2:281-289.
5. Karimi M, Goldie LC, Ulgiati D, Abraham LJ: Integration site-spe-
cific transcriptional reporter gene analysis using Flp recom-
binase targeted cell lines.  Biotechniques 2007, 42:217-224.
6. Stewart SG, Spagnolo D, Polomska ME, Sin M, Karimi M, Abraham LJ:
Synthesis and TNF expression inhibitory properties of new
thalidomide analogues derived via Heck cross coupling.
Bioorg Med Chem Lett 2007, 17:5819-5824.
7. Thomas KR, Capecchi MR: Targeting of genes to specific sites in
the mammalian genome.  Cold Spring Harb Symp Quant Biol 1986,
51:1101-1113.
8. Inoue N, Hirata RK, Russell DW: High-fidelity correction of
mutations at multiple chromosomal positions by adeno-
associated virus vectors.  J Virol 1999, 73:7376-7380.
9. Rogers CS, Hao Y, Rokhlina T, Samuel M, Stoltz DA, Li Y, Petroff E,
Vermeer DW, Kabel AC, Yan Z, Spate L, Wax D, Murphy CN, Rieke
A, Whitworth K, Linville ML, Korte SW, Engelhardt JF, Welsh MJ,Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Biology 2009, 7:8 http://www.biomedcentral.com/1741-7007/7/8
Page 10 of 10
(page number not for citation purposes)
Prather RS: Production of CFTR-null and CFTR-DeltaF508
heterozygous pigs by adeno-associated virus-mediated gene
targeting and somatic cell nuclear transfer.  J Clin Invest 2008,
118:1571-1577.
10. Russell DW, Hirata RK, Inoue N: Validation of AAV-mediated
gene targeting.  Nat Biotechnol 2002, 20:658.
11. Sun X, Yan Z, Yi Y, Li Z, Lei D, Rogers CS, Chen J, Zhang Y, Welsh
MJ, Leno GH, Engelhardt JF: Adeno-associated virus-targeted
disruption of the CFTR gene in cloned ferrets.  J Clin Invest
2008, 118:1578-1583.
12. Fernandez SL, Russell DW, Hurlin PJ: Development of human
gene reporter cell lines using rAAV mediated homologous
recombination.  Biol Proced Online 2007, 9:84-90.
13. Hendrie PC, Russell DW: Gene targeting with viral vectors.  Mol
Ther 2005, 12:9-17.
14. Vasileva A, Jessberger R: Precise hit: adeno-associated virus in
gene targeting.  Nat Rev Microbiol 2005, 3:837-847.
15. McCarty DM, Monahan PE, Samulski RJ: Self-complementary
recombinant adeno-associated virus (scAAV) vectors pro-
mote efficient transduction independently of DNA synthesis.
Gene Ther 2001, 8:1248-1254.
16. Hirata RK, Russell DW: Design and packaging of adeno-associ-
ated virus gene targeting vectors.  J Virol 2000, 74:4612-4620.
17. Old LJ: Tumor necrosis factor (TNF).  Science 1985,
230:630-632.
18. Nedwin GE, Svedersky LP, Bringman TS, Palladino MA Jr, Goeddel
DV: Effect of interleukin 2, interferon-gamma, and mitogens
on the production of tumor necrosis factors alpha and beta.
J Immunol 1985, 135:2492-2497.
19. Raetz CR, Ulevitch RJ, Wright SD, Sibley CH, Ding A, Nathan CF:
Gram-negative endotoxin: an extraordinary lipid with pro-
found effects on eukaryotic signal transduction.  Faseb J 1991,
5:2652-2660.
20. Barthel R, Goldfeld AE: T cell-specific expression of the human
TNF-alpha gene involves a functional and highly conserved
chromatin signature in intron 3.  J Immunol 2003, 171:3612-3619.
21. Murakami T, Mataki C, Nagao C, Umetani M, Wada Y, Ishii M, Tsut-
sumi S, Kohro T, Saiura A, Aburatani H, Hamakubo T, Kodama T:
The gene expression profile of human umbilical vein
endothelial cells stimulated by tumor necrosis factor alpha
using DNA microarray analysis.  J Atheroscler Thromb 2000,
7:39-44.
22. Haranaka K, Carswell EA, Williamson BD, Prendergast JS, Satomi N,
Old LJ: Purification, characterization, and antitumor activity
of nonrecombinant mouse tumor necrosis factor.  Proc Natl
Acad Sci USA 1986, 83:3949-3953.
23. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor
superfamilies: integrating mammalian biology.  Cell 2001,
104:487-501.
24. Wajant H, Pfizenmaier K, Scheurich P: Tumor necrosis factor sig-
naling.  Cell Death Differ 2003, 10:45-65.
25. Beutler B, Brown T: A CAT reporter construct allows ultrasen-
sitive estimation of TNF synthesis, and suggests that the
TNF gene has been silenced in non-macrophage cell lines.  J
Clin Invest 1991, 87:1336-1344.
26. Seiler-Tuyns A, Dufour N, Spertini F: Human tumor necrosis fac-
tor-alpha gene 3' untranslated region confers inducible toxin
responsiveness to homologous promoter in monocytic THP-
1 cells.  J Biol Chem 1999, 274:21714-21718.
27. Kruys V, Kemmer K, Shakhov A, Jongeneel V, Beutler B: Constitu-
tive activity of the tumor necrosis factor promoter is can-
celed by the 3' untranslated region in nonmacrophage cell
lines; a trans-dominant factor overcomes this suppressive
effect.  Proc Natl Acad Sci USA 1992, 89:673-677.
28. Baena A, Mootnick AR, Falvo JV, Tsytskova AV, Ligeiro F, Diop OM,
Brieva C, Gagneux P, O'Brien SJ, Ryder OA, Goldfeld AE: Primate
TNF promoters reveal markers of phylogeny and evolution
of innate immunity.  PLoS ONE 2007, 2:e621.
29. Tsytsykova AV, Falvo JV, Schmidt-Supprian M, Courtois G, Thanos D,
Goldfeld AE: Post-induction, stimulus-specific regulation of
tumor necrosis factor mRNA expression.  J Biol Chem 2007,
282:11629-11638.
30. Tsytsykova AV, Rajsbaum R, Falvo JV, Ligeiro F, Neely SR, Goldfeld
AE:  Activation-dependent intrachromosomal interactions
formed by the TNF gene promoter and two distal enhanc-
ers.  Proc Natl Acad Sci USA 2007, 104:16850-16855.
31. Sullivan KE, Reddy AB, Dietzmann K, Suriano AR, Kocieda VP, Stew-
art M, Bhatia M: Epigenetic regulation of tumor necrosis factor
alpha.  Mol Cell Biol 2007, 27:5147-5160.
32. Goldfeld AE, Maniatis T: Coordinate viral induction of tumor
necrosis factor alpha and interferon beta in human B cells
and monocytes.  Proc Natl Acad Sci USA 1989, 86:1490-1494.
33. Goldfeld AE, Strominger JL, Doyle C: Human tumor necrosis fac-
tor alpha gene regulation in phorbol ester stimulated T and
B cell lines.  J Exp Med 1991, 174:73-81.
34. Niiya M, Niiya K, Kiguchi T, Shibakura M, Asaumi N, Shinagawa K, Ishi-
maru F, Kiura K, Ikeda K, Ueoka H, Tanimoto M: Induction of TNF-
alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung
carcinoma cells.  Cancer Chemother Pharmacol 2003, 52:391-398.
35. Tangpong J, Cole MP, Sultana R, Joshi G, Estus S, Vore M, St Clair W,
Ratanachaiyavong S, St Clair DK, Butterfield DA: Adriamycin-
induced, TNF-alpha-mediated central nervous system toxic-
ity.  Neurobiol Dis 2006, 23:127-139.
36. Lee JY, Kim NA, Sanford A, Sullivan KE: Histone acetylation and
chromatin conformation are regulated separately at the
TNF-alpha promoter in monocytes and macrophages.  J Leu-
koc Biol 2003, 73:862-871.
37. Rewcastle GW, Atwell GJ, Li ZA, Baguley BC, Denny WA: Potential
antitumor agents. 61. Structure-activity relationships for in
vivo colon 38 activity among disubstituted 9-oxo-9H-xan-
thene-4-acetic acids.  J Med Chem 1991, 34:217-222.
38. Ching LM, Goldsmith D, Joseph WR, Korner H, Sedgwick JD, Baguley
BC: Induction of intratumoral tumor necrosis factor (TNF)
synthesis and hemorrhagic necrosis by 5,6-dimethylxanthe-
none-4-acetic acid (DMXAA) in TNF knockout mice.  Cancer
Res 1999, 59:3304-3307.
39. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching LM:
Stimulation of tumors to synthesize tumor necrosis factor-
alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a
novel approach to cancer therapy.  Cancer Res 1999, 59:633-638.
40. Cai SX: Small molecule vascular disrupting agents: potential
new drugs for cancer treatment.  Recent Pat Anticancer Drug Dis-
cov 2007, 2:79-101.
41. Yan Z, Lei-Butters DC, Liu X, Zhang Y, Zhang L, Luo M, Zak R, Engel-
hardt JF: Unique biologic properties of recombinant AAV1
transduction in polarized human airway epithelia.  J Biol Chem
2006, 281:29684-29692.